Johannes Aerts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Johannes Aerts has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Gali Maor
Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv University, 69978 Ramat Aviv, Israel
1 shared publication - Maria Joao Ferraz
Department of Medical Biochemistry and Department of Bio‐organic Synthesis Leiden Institute of Chemistry (LIC) Leiden University Leiden the Netherlands
1 shared publication - Metsada Pasmanik-Chor
Bioinformatics Unit, Faculty of life Science, Tel Aviv University, Ramat Aviv 69978, Israel
1 shared publication - Mia Horowitz
Shmunis School of Biomedicine and Cancer Research, Tel-Aviv University , Levanon St., Tel Aviv 69978
1 shared publication - Mina Mirzaian
Leiden Institute of Chemistry, Leiden University, 9502 Leiden, The Netherlands
1 shared publication - Olga Krivoruk
School of Molecular Cell Biology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69978, Israel
1 shared publication
Latest Publications
- Open Access
- 9 September 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (9) , 1420
Drosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
Gaucher disease (GD) results from mutations in the GBA1 gene, which encodes lysosomal glucocerebrosidase (GCase). The large number of mutations known to date in the gene lead to a heterogeneous disorder, which is divided into a non-neuronopathic, type 1 GD, and two neurological, type 2 and type 3, forms. We studied the two fly GBA1 orthologs, GBA1a and GBA1b. Each contains a Minos element insertion, which truncates its coding sequence. In the GBA1am/m flies, which express a mutant protein, missing 33 C-terminal amino acids, there was no decrease in GCase activity or substrate accumulation. However, GBA1bm/m mutant flies presented a significant decrease in GCase activity with concomitant substrate accumulation, which included C14:1 glucosylceramide and C14:0 glucosylsphingosine. GBA1bm/m mutant flies showed activation of the Unfolded Protein Response (UPR) and presented inflammation and neuroinflammation that culminated in development of a neuronopathic disease. Treatment with ambroxol did not rescue GCase activity or reduce substrate accumulation; however, it ameliorated UPR, inflammation and neuroinflammation, and increased life span. Our results highlight the resemblance between the phenotype of the GBA1bm/m mutant fly and neuronopathic GD and underlie its relevance in further GD studies as well as a model to test possible therapeutic modalities.
- 9 September 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (9) , 1420
Open AccessDrosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
Gaucher disease (GD) results from mutations in the GBA1 gene, which encodes lysosomal glucocerebrosidase (GCase). The large number of mutations known to date in the gene lead to a heterogeneous disorder, which is divided into a non-neuronopathic, type 1 GD, and two neurological, type 2 and type 3, forms. We studied the two fly GBA1 orthologs, GBA1a and GBA1b. Each contains a Minos element insertion, which truncates its coding sequence. In the GBA1am/m flies, which express a mutant protein, missing 33 C-terminal amino acids, there was no decrease in GCase activity or substrate accumulation. However, GBA1bm/m mutant flies presented a significant decrease in GCase activity with concomitant substrate accumulation, which included C14:1 glucosylceramide and C14:0 glucosylsphingosine. GBA1bm/m mutant flies showed activation of the Unfolded Protein Response (UPR) and presented inflammation and neuroinflammation that culminated in development of a neuronopathic disease. Treatment with ambroxol did not rescue GCase activity or reduce substrate accumulation; however, it ameliorated UPR, inflammation and neuroinflammation, and increased life span. Our results highlight the resemblance between the phenotype of the GBA1bm/m mutant fly and neuronopathic GD and underlie its relevance in further GD studies as well as a model to test possible therapeutic modalities.